An Overview of Tuberculosis Chemotherapy - A Literature Review

被引:28
作者
Sarkar, Susmita [1 ]
Suresh, Mavanur R. [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
来源
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES | 2011年 / 14卷 / 02期
关键词
RESISTANT MYCOBACTERIUM-TUBERCULOSIS; ENCAPSULATED ANTITUBERCULAR DRUGS; NECROSIS-FACTOR-ALPHA; VITAMIN-D; PEPTIDE DEFORMYLASE; INTERFERON-GAMMA; MACROPHAGE PHAGOCYTOSIS; PULMONARY TUBERCULOSIS; MICROSPHERE TECHNOLOGY; COST-EFFECTIVENESS;
D O I
10.18433/J33591
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tuberculosis (TB) is a major global health threat. The emergence of human immunodeficiency virus (HIV) and also multi drug resistant (MDR) and extremely drug resistant (XDR)-TB poses a vital challenge to the control of the disease. For the last 50 years, no new anti-TB drug has been discovered. This literature review provides a brief discussion of existing drugs and emerging drug targets, and also of the advantages of incorporating modern drug delivery systems and immune modulators in order to improve the existing treatment regimen in terms of better efficacy, reduced drug administration frequency, shortened period of treatment and reduced drug related toxicity. The investigation for a new drug target is essential to continue the battle against MDR and XDR-TB. However, owing to the enormous cost and time involved in new drug development, improvement of the existing treatment regimen is seen to be a valid alternative.
引用
收藏
页码:148 / 161
页数:14
相关论文
共 110 条
[1]  
Akasaka Y, 1988, Drug Des Deliv, V3, P85
[2]   The clinical use of fluoroquinolones for the treatment of mycobacterial diseases [J].
Alangaden, GJ ;
Lerner, SA .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) :1213-1221
[3]   Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency [J].
Altare, F ;
Durandy, A ;
Lammas, D ;
Emile, JF ;
Lamhamedi, S ;
Le Deist, F ;
Drysdale, P ;
Jouanguy, E ;
Döffinger, R ;
Bernaudin, F ;
Jeppsson, O ;
Gollob, JA ;
Meinl, E ;
Segal, AW ;
Fischer, A ;
Kumararatne, D ;
Casanova, JL .
SCIENCE, 1998, 280 (5368) :1432-1435
[4]   Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis [J].
Amaral, L ;
Kristiansen, JE ;
Abebe, LS ;
Millett, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (06) :1049-1053
[5]   Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies [J].
Amaral, L ;
Kristiansen, JE .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (03) :173-176
[6]   Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis:: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy [J].
Amaral, L ;
Kristiansen, JE ;
Viveiros, M ;
Atouguia, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (05) :505-511
[7]   MECHANISM OF WALL SYNTHESIS IN BACTERIA - ORGANIZATION OF ENZYMES AND ISOPRENOID PHOSPHATES IN MEMBRANE [J].
ANDERSON, RG ;
BADDILEY, J ;
HUSSEY, H .
BIOCHEMICAL JOURNAL, 1972, 127 (01) :11-+
[8]   A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].
Andries, K ;
Verhasselt, P ;
Guillemont, J ;
Göhlmann, HWH ;
Neefs, JM ;
Winkler, H ;
Van Gestel, J ;
Timmerman, P ;
Zhu, M ;
Lee, E ;
Williams, P ;
de Chaffoy, D ;
Huitric, E ;
Hoffner, S ;
Cambau, E ;
Truffot-Pernot, C ;
Lounis, N ;
Jarlier, V .
SCIENCE, 2005, 307 (5707) :223-227
[9]  
[Anonymous], WHO TB REP
[10]   Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages [J].
Barrow, ELW ;
Winchester, GA ;
Staas, JK ;
Quenelle, DC ;
Barrow, WW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2682-2689